Skip Navigation

Vaccine Safety Bibliography - January 2013

1.   Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - burkina faso and mali. MMWR Morb Mortal Wkly Rep. 2012 Dec 21; 61:1025-8.

2.   Priorities for research on meningocccal disease and the impact of serogroup A  vaccination in the African meningitis belt. Vaccine. 2012 Dec 27.  [Epub ahead of print].

3.   Recommendation of WHO Strategic Advisory Group of Experts (SAGE) on Immunization. Pediatrics. 2013 Jan; 131(1):e343.

4.   Serogroup a meningococcal conjugate vaccine coverage after the first national mass immunization campaign -  burkina faso, 2011. MMWR Morb Mortal Wkly Rep. 2012 Dec 21; 61:1022-4.

5.   The power of suggestion: Adverse events from inactivated vaccines mimic the disease. J Paediatr Child Health. 2012 Dec; 48(12):1101-2.

6.   Abebe DS, Nielsen VO, Finnvold JE. Regional inequality and vaccine uptake: a multilevel analysis of the 2007 Welfare Monitoring Survey in Malawi. BMC Public Health. 2012 Dec 13; 12(1):1075. [Epub ahead of print].

7.   Al-Lela OQ, Bahari MB, Elkalmi RM, Jawad Awadh AI. Incorporating an immunization course in the pharmacy curriculum: malaysian experience. Am J Pharm  Educ. 2012 Dec 12; 76(10):206.

8.   Al-Lela OQ, Baidi Bahari M, Al-Abbassi MG, Salih MR, Basher AY. Influence of health providers on pediatrics' immunization rate. J Trop Pediatr. 2012 Dec; 58(6):441-5.

9.   Amaro ML, Lutfiyya MN, Akers MF, Swanoski MT. Examination of pneumococcal vaccination rates among U.S. adult smokers. Am J Health Syst Pharm. 2012 Dec 15; 69(24):2154-8.

10.  Ambrose CS, Wu X. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Vaccine. 2012 Dec 19. [Epub ahead of print].

11.  Anekwe TD, Kumar S. The effect of a vaccination program on child anthropometry: evidence from India's Universal Immunization Program. J PublicHealth (Oxf). 2012 Dec; 34(4):489-97.

12.  Arinaminpathy N, Lavine JS, Grenfell BT. Self-boosting vaccines and their implications for herd immunity. Proc Natl Acad Sci U S A. 2012 Dec4; 109(49):20154-9.

13.  Arnheim-Dahlström L, Hällgren J, Weibull CE, Sparén P. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. BMJ. 2012 Dec 18; 345:e7594.

14.  Ashry el SH, Ahmad TA. The use of propolis as vaccine's adjuvant. Vaccine. 2012 Dec 17; 31(1):31-9.

15.  Bakhache P, Rodrigo C, Davie S, Ahuja A, Sudovar B, Crudup T, Rose M. Health  care providers' and parents' attitudes toward administration of new infant vaccines-a multinational survey. Eur J Pediatr. 2012 Dec 28. [Epub ahead of print].

16.  Bakir M, Standaert B, Turel O, Bilge E, Postma M. Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model. Vaccine. 2012 Dec 6. [Epub ahead of print].

17.  Barr IG, Jelley LL. The Coming Era of Quadrivalent Human Influenza Vaccines:  Who will Benefit? Drugs. 2012 Dec 3; 72(17):2177-85.

18.  Beeler JA, Eichelberger MC. Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy. Microb Pathog. 2012Dec 13. [Epub ahead of print].

19.  Bellido-Blasco JB, Sabater-Vidal S, Salvador-Ribera Mdel M, Arnedo-Pena A, Tirado-Balaguer MD, Meseguer-Ferrer N, Silvestre-Silvestre E, Romeu-García MÀ, Herrero-Carot C, Moreno-Muñoz MR. Rotavirus vaccination effectiveness: A case-case study in the EDICS project, Castellón (Spain). Vaccine. 2012 Dec 14; 30(52):7536-40.

20.  Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E. Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects. Clin Vaccine Immunol. 2012 Dec; 19(12):1943-8.

21.  Birnbaum MS, Jacobs ET, Ralston-King J, Ernst KC. Correlates of high vaccination exemption rates among kindergartens. Vaccine. 2012 Dec 13. [Epub ahead of print].

22.  Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, Hou V, Pehlic V, Yuan T, Gurunathan S. Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine. 2012 Dec 14; 30(52):7461-8.

23.  Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis. 2012Dec; 60(6):959-65.

24.  Bonds RS, Kelly BC. Severe Serum Sickness After H1N1 Influenza Vaccination. Am J Med Sci. 2012 Dec 5. [Epub ahead of print].

25.  Breiman A, Carpentier DC, Ewles HA, Smith GL. Transport and stability of the vaccinia virus A34 protein is affected by the A33 protein. J Gen Virol. 2012 Dec 19. [Epub ahead of print].

26.  Brennan MJ, Stone MR, Evans T. A rational vaccine pipeline for tuberculosis.  Int J Tuberc Lung Dis. 2012 Dec; 16(12):1566-73.

27.  Buricchi F, Bardelli M, Malzone C, Capecchi B, Nicolay U, Fragapane E, Castellino F, Del Giudice G, Galli G, Finco O. Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus. Eur J Immunol. 2012 Dec 13.  [Epub ahead of print].

28.  Caldeira NG, de Filippis I, Catão Arruda T, Côrte Real ME, Batalha de Jesus A, de Almeida AE. Haemophilus influenzae serotype b and a capsule-deficient type mutant (b-)invasive disease on a partially vaccinated child in Brazil. J Med Microbiol. 2012 Dec 21. [Epub ahead of print].

29.  Callado RB, Ponte Carneiro TG, da Cunha Parahyba CC, de Alcantara Lima N, da  Silva Junior GB, de Francesco Daher E. Rhabdomyolysis secondary to influenza A H1N1 vaccine resulting in acute kidney injury. Travel Med Infect Dis. 2012 Dec 3. [Epub ahead of  print].

30.  Campi-Azevedo AC, de Araújo-Porto LP, Luiza-Silva M, Batista MA, Martins MA,  Sathler-Avelar R, da Silveira-Lemos D, Camacho LA, de Menezes Martins R, de Lourdes de Sousa Maia M, Farias RH, da Silva Freire M, Galler R, Homma A, Ribeiro JG, Lemos JA, Auxiliadora-Martins M, Caldas IR, Elói-Santos SM, Teixeira-Carvalho A, Martins-Filho OA. 17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children. PLoS One. 2012;7(12):e49828.

31.  Cayabyab MJ, Macovei L, Campos-Neto A. Current and novel approaches to vaccine development against tuberculosis. Front Cell Infect Microbiol.2012; 2:154.

32.  Charfi F, Smaoui H, Kechrid A. Non-susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population:  A 10-year study. Vaccine. 2012 Dec 31; 30 Suppl 6:G18-24.

33.  Chatterjee P. Advertising watchdog bans "misleading" commercial on rotavirus vaccination. BMJ. 2012 Dec 27; 345:e8682.

34.  Chen JY, Chang CY, Lin YS, Hu ML. Nutritional factors in herpes zoster, postherpetic neuralgia, and zoster vaccination. Popul Health Manag. 2012 Dec; 15(6):391-7.

35.  Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine. 2012 Dec 17;31(1):159-64.    

36.  Chiu PJ, Chen CH, Chih YC. Effectiveness of the influenza vaccination program for the elderly in Taiwan. Vaccine. 2012 Dec 1. [Epub ahead of print].

37.  Choe YJ, Bae GR, Lee DH. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: An ecological study. Vaccine. 2012 Dec14; 30(52):7439-42.

38.  Chol C, Guy C, Jacquet A, Castot-Villepelet A, Kreft-Jais C, Cambazard F, Beyens MN, Mounier G, Marsille F, Mismetti P. Complications of BCG vaccine SSI®recent story and risk management plan: the French experience. Pharmacoepidemiol Drug Saf. 2012 Dec 5. [Epub ahead of print].

39.  Cohen R, Levy C, Bechet S, Elbez A, Corrard F. [How pediatricians and GP consider the implementation of meningococal B vaccination in France?]. ArchPediatr. 2012 Dec; 19(12):1379-85.

40.  Coleman AS, Akkoyunlu M. Bacterial polysaccharide mediated downregulation of TACI and B cell apoptosis contribute to the hyporesponsiveness against bacterial polysaccharides vaccines. J Infect Dis. 2012 Dec 13. [Epub ahead of print].

41.  Colombatti R, Montanaro M, Guasti F, Rampazzo P, Meneghetti G, Giordan M, Basso G, Sainati L. Comprehensive care for sickle cell disease immigrant patients: a reproducible model achieving high adherence to minimum standards of care. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1275-9.

42.  Connors J, Arushanyan E, Bellanca G, Racine R, Hoeffler A, Delgado A, Gibbons S. A description of barriers and facilitators to childhood vaccinations in the military health system. J Am Acad Nurse Pract. 2012 Dec; 24(12):716-25.

43.  Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant. 2012 Dec; 17(6):601-8.

44.  Coskun-Ari FF, Guldemir D, Durmaz R. One-Step Multiplex PCR Assay for Detecting Streptococcus pneumoniae Serogroups/Types Covered by 13-Valent Pneumococcal Conjugate Vaccine (PCV13). PLoS One. 2012;7(12):e50406.

45.  Couch RB, Decker WK, Utama B, Atmar RL, Niño D, Feng JQ, Halpert MM, Air GM.  Evaluations for in vitro correlates of immunogenicity of inactivated influenza a h5, h7 and h9 vaccines in humans. PLoS One. 2012; 7(12):e50830.

46.  Couch RB, Patel SM, Wade-Bowers CL, Niño D. A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine. PLoS One. 2012;7(12):e49704.

47.  Coudeville L, Garnett GP. Transmission dynamics of the four dengue serotypes  in southern Vietnam and the potential impact of vaccination. PLoS One. 2012; 7(12):e51244.

48.  Crocker J, Porter-Jones G, McGowan A, Roberts RJ, Cottrell S. Teenage booster vaccine: factors affecting uptake. J Public Health (Oxf). 2012 Dec; 34(4):498-504.

49.  Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups a, C, w135 and y) tetanus toxoid conjugate vaccine (nimenrixTM). Drugs. 2012 Dec 24; 72(18):2407-30.

50.  D'Onise K, Almond S, Macdonald B, Watson M, Scrimgeour S. Have purpose-built  vaccine refrigerators reduced the cost of vaccine losses in South Australia? Aust N Z J Public Health. 2012 Dec; 36(6):572-6.

51.  Daily JP. Malaria vaccine trials--beyond efficacy end points. N Engl J Med. 2012 Dec 13; 367(24):2349-51.

52.  Darsley MJ, Chakraborty S, Denearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD. The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease. Clin Vaccine Immunol. 2012 Dec; 19(12):1921-31.

53.  de Whalley PC, Pollard AJ. Pandemic influenza A (H1N1) 2009 vaccination in children: A UK perspective. J Paediatr Child Health. 2012 Dec 16. [Epub ahead of print].

54.  Derber CJ, Shankaran S. Health-care worker vaccination for influenza: strategies and controversies. Curr Infect Dis Rep. 2012 Dec; 14(6):627-32.

55.  Diazgranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009-201 season. Vaccine. 2012 Dec 18.  [Epub ahead of print].

56.  Diazgranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and  its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials. Vaccine. 2012 Dec 17; 31(1):49-57.

57.  Donohoe KL, Mawyer TM, Stevens JT, Morgan LA, Harpe SE. An active-learning laboratory on immunizations. Am J Pharm Educ. 2012 Dec 12; 76(10):198.

58.  Dorell C, Yankey D, Kennedy A, Stokley S. Factors That Influence Parental Vaccination Decisions for Adolescents, 13 to 17 Years Old: National Immunization  Survey-Teen, 2010. Clin Pediatr (Phila). 2012 Dec 6. [Epub ahead of print].

59.  Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol. 2012 Dec; 10(12):807-13.

60.  Dubé E, Bettinger JA, Halperin B, Bradet R, Lavoie F, Sauvageau C, Gilca V,Boulianne N. Determinants of parents' decision to vaccinate their children against rotavirus: results of a longitudinal study. Health Educ Res. 2012 Dec; 27(6):1069-1080.

61.  Duclos P, Durrheim DN, Reingold AL, Bhutta ZA, Vannice K, Rees H. Developing  evidence-based immunization recommendations and GRADE. Vaccine. 2012 Dec 17; 31(1):12-9.

62.  Elberse KE, van der Heide HG, Witteveen S, van de Pol I, Schot CS, van der Ende A, Berbers GA, Schouls LM. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2012 Dec 14; 30(52):7644-51.

63.  Elmdaghri N, Benbachir M, Belabbes H, Zaki B, Benzaid H. Changing epidemiology of pediatric Streptococcus pneumoniae isolates before vaccine introduction in Casablanca (Morocco). Vaccine. 2012 Dec 31; 30 Suppl 6:G46-50.

64.  Elvidge S. Merck tests needle-free vaccines. Nat Biotechnol. 2012 Dec 7; 30(12):1155.

65.  Erlich P, Sansonetti PJ. [Acute intestinal infections: Current and upcoming vaccines.]. Presse Med. 2012 Dec 10. [Epub ahead of print].

66.  Ernsting A, Gellert P, Schneider M, Lippke S. A mediator model to predict workplace influenza vaccination behaviour - an application of the health action process approach. Psychol Health. 2012 Dec 24. [Epub ahead of print].

67.  Esen M, Mordmüller B, de Salazar PM, Adegnika AA, Agnandji ST, Schaumburg F,  Hounkpatin AB, Brückner S, Theisen M, Bélard S, Ngoa UA, Issifou S, Yazdanbakhsh  M, Kremsner PG. Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine. 2012 Dec 14; 30(52):7621-4.

68.  Fairhead T, Hendren E, Tinckam K, Rose C, Sherlock CH, Shi L, Crowcroft NS, Gubbay JB, Landsberg D, Knoll G, Gill J, Kumar D. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Transpl Infect Dis. 2012 Dec; 14(6):575-83.

69.  Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P, Mennini FS. Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases: The BEST Study. Med Care. 2012 Dec; 50(12):1076-1085.

70.  Fisman DN, Chan CH, Lowcock E, Naus M, Lee V. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: A model-based evaluation. Vaccine. 2012 Dec 14; 30(52):7601-7.

71.  Fowkes FJ, McGready R, Johnstone-Robertson S, Nosten F, Beeson JG. Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy. Clin Infect Dis. 2012 Dec 18. [Epub ahead of print].

72.  Freitas DR, Moura E, Araújo G, Cardoso A, Scheidt P, Ferraz E, Madalosso G, Chen RT, Hatch DL. Investigation of an outbreak of hypersensitivity-type reactions during the 2004 national measles-mumps-rubella vaccination campaign in Brazil. Vaccine. 2012 Dec 13.  [Epub ahead of print].

73.  Fried M, Avril M, Chaturvedi R, Fernandez P, Lograsso J, Narum D, Nielsen MA, Oleinikov AV, Resende M, Salanti A, Saveria T, Williamson K, Dicko A, Scherf A, Smith JD, Theander TG, Duffy PE. Preclinical evaluation of pregnancy malaria vaccine immunogens: a multi-laboratory approach. Infect Immun. 2012 Dec 3. [Epub ahead of print].

74.  Fu C, He Q, Xu J, Xie H, Ding P, Hu W, Dong Z, Liu X, Wang M. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine. 2012 Dec 17; 31(1):154-8.

75.  Fukushima W, Ohfuji S, Deguchi M, Kawabata K, Hatayama H, Yoshida H, Maeda A, Hirota Y. Effectiveness of an influenza A (H1N1) 2009 monovalent vaccine among Japanese pregnant women: A prospective observational study assessing antibody efficacy. Vaccine. 2012 Dec 14; 30(52):7630-6.

76.  Gainforth HL, Cao W, Latimer-Cheung AE. Determinants of Human Papillomavirus  (HPV) Vaccination Intent Among Three Canadian Target Groups. J Cancer Educ. 2012 Dec; 27(4):717-24.

77.  García-López R, Pérez-Brocal V, Diez-Domingo J, Moya A. Gut microbiota in children vaccinated with rotavirus vaccine. Pediatr Infect Dis J. 2012 Dec; 31(12):1300-2.

78.  Garg R, Shrivastava P, van Drunen Littel-van den Hurk S. The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. Expert Rev Vaccines. 2012 Dec; 11(12):1441-57.

79.  Garnock-Jones KP, Giuliano AR. Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males†: Profile Report. Drugs R D. 2012 Dec 1; 12(4):235-8.

80.  Gauvreau CL, Ungar WJ, Köhler JC, Zlotkin S. The use of cost-effectiveness analysis for pediatric immunization in developing countries. Milbank Q. 2012 Dec; 90(4):762-90.

81.  Gerberding J, Yawn BP. Discussing the zoster vaccine: an interview with julie gerberding, president of merck vaccines. Popul Health Manag. 2012 Dec; 15(6):382-4.

82.  Gibney KB, Edupuganti S, Panella AJ, Kosoy OI, Delorey MJ, Lanciotti RS, Mulligan MJ, Fischer M, Staples JE. Detection of anti-yellow Fever virus immunoglobulin m antibodies at 3-4 years following yellow Fever vaccination. Am J Trop Med Hyg. 2012 Dec; 87(6):1112-5.

83.  Granoff DM. European Medicines Agency Recommends Approval of a Broadly Protective Vaccine against Serogroup B Meningococcal Disease. Pediatr Infect Dis J. 2012 Dec 19. [Epub ahead of print].

84.  Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.  Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2012 Dec 8. [Epub ahead of print].

85.  Greenhawt MJ, Spergel JM, Rank MA, Green TD, Masnoor D, Sharma H, Bird JA, Chang JE, Sinh D, Teich E, Kelso JM, Sanders GM. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. Ann Allergy Asthma Immunol. 2012 Dec; 109(6):426-30.

86.  Grimaldi-Bensouda L, Michel M, Aubrun E, Leighton P, Viallard JF, Adoue D, Magy-Bertrand N, Tisserand G, Khellaf M, Durand JM, Quittet P, Fain O, Bonnotte B, Morin AS, Limal N, Costedoat-Chalumeau N, Morel N, Pan-Petesch B, Decaux O, Mahevas M, Ruel M, Sacre K, Lefrere F, Abenhaim L, Godeau B; for the PGRx Immune  Thrombocytopenia Study Group. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood. 2012 Dec 13; 120(25):4938-4944.

87.  Groom AV, Santibanez TA, Bryan RT. Vaccination coverage among american Indian and alaska native children, 2006-2010. Pediatrics. 2012 Dec; 130(6):e1592-9.

88.  Gulland A. Six polio vaccination workers are shot dead in Pakistan. BMJ. 2012 Dec 19; 345:e8609.

89.  Hariri S, Markowitz L. Monitoring HPV vaccine impact: early results and ongoing challenges. J Infect Dis. 2012 Dec 1; 206(11):1633-5.

90.  Hawken S, Manuel DG, Deeks SL, Kwong JC, Crowcroft NS, Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am J Epidemiol. 2012 Dec 1; 176(11):1035-42.

91.  He Y, Zarychta A, Ranz JB, Carroll M, Singleton LM, Wilson PM, Schlaudecker  EP. Childhood immunization rates in rural Intibuca, Honduras: An analysis of a local database tool and community health center records for assessing and improving vaccine coverage. BMC Public Health. 2012 Dec 7; 12(1):1056. [Epub ahead of print].

92.  He Y, Toldo L, Burns G, Tao C, Abernethy DR. A 2012 Workshop: Vaccine and Drug Ontology in the Study of Mechanism and Effect (VDOSME 2012). J Biomed Semantics. 2012 Dec 18; 3(1):12. [Epub ahead of print].

93.  Head S, Atkin S, Allan K, Ferguson C, Lutchmun S, Cordery R. Vaccinating health care workers during an influenza pandemic. Occup Med (Lond). 2012 Dec; 62(8):651-4.

94.  Healy CM, Rench MA, Baker CJ. Importance of Timing of Maternal Combined Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Immunization and Protection of Young Infants. Clin Infect Dis. 2012 Dec 12. [Epub ahead of print].

95.  Hechter RC, Qian L, Sy LS, Greene SK, Weintraub ES, Naleway AL, Rowhani-Rahbar A, Donahue JG, Daley MF, Vazquez-Benitez G, Lugg MM, Jacobsen SJ.  Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink Project. Vaccine. 2012 Dec 22. [Epub ahead of print].

96.  Heidebrecht CL, Quach S, Pereira JA, Quan SD, Kolbe F, Finkelstein M, Buckeridge DL, Kwong JC; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Vaccine Coverage Theme Group.  Incorporating scannable forms into immunization data collection processes: a mixed-methods study. PLoS One. 2012; 7(12):e49627.

97.  Heikkinen T, Block SL, Toback SL, Wu X, Ambrose CS. Effectiveness of Intranasal Live Attenuated Influenza Vaccine against All-cause Acute Otitis Media in Children. Pediatr Infect Dis J. 2012 Dec 26. [Epub ahead of print].

98.  Henkle E, Steinhoff MC, Omer SB, Roy E, Arifeen SE, Raqib R, Breiman RF, Caulfield LE, Moss WJ, Zaman K. The Effect of Exclusive Breastfeeding on Respiratory Illness in Young Infants in a Maternal Immunization Trial in Bangladesh. Pediatr Infect Dis J. 2012 Dec 17. [Epub ahead of print].

99.  Hernández-García I, Domínguez B, González R. Influenza vaccination rates and determinants among Spanish medical students. Vaccine. 2012 Dec 17; 31(1):1-2.

100. Hewitt N, Levinson M, Stephenson G. Drug reaction with eosinophilia and systemic symptoms associated with H1N1 vaccination. Intern Med J. 2012 Dec; 42(12):1365-6.

101. Hof H, Fahr A, Holfelder M, Schwarz R, Oberdorfer K. [Severe pneumococcal infections in the elderly - preventable by vaccination.]. Z Gerontol Geriatr. 2012 Dec 20. [Epub ahead of print].

102. Hofstetter AM, Natarajan K, Martinez RA, Rabinowitz D, Vawdrey DK, Stockwell MS. Influenza vaccination coverage and timeliness among children requiring two doses, 2004-2009. Prev Med. 2012 Dec 3.  [Epub ahead of print].

103. Hollander D. Parents, Adolescent Sons Open to Variety of Settings For HPV Vaccination. Perspect Sex Reprod Health. 2012 Dec; 44(4):271-2.

104. Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2012 Dec 20. [Epub ahead of print].

105. Horsington J, Turnbull L, Whitchurch CB, Newsome TP. Sub-viral imaging of vaccinia virus using super-resolution microscopy. J Virol Methods. 2012 Dec; 186(1-2):132-6.

106. Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Survelliance for adverse events following immunization from 2008 to 2011 in Zhejiang province, China. Clin Vaccine Immunol. 2012 Dec 12. [Epub ahead of print].

107. Huang JH, Miao YY, Kuo PC. Pandemic influenza H1N1 vaccination intention: psychosocial determinants and implications from a national survey, Taiwan. Eur J Public Health. 2012 Dec; 22(6):796-801.

108. Hur J, Ozgür A, Xiang Z, He Y. Identification of fever and vaccine-associated gene interaction networks using ontology-based literature mining. J Biomed Semantics. 2012 Dec 20; 3(1):18. [Epub ahead of print].

109. Ikeya S, Urano S, Tokura Y. Linear IgA bullous dermatosis following human papillomavirus vaccination. Eur J Dermatol. 2012 Dec 1; 22(6):787-8.

110. Islam MA, Firdous J, Choi YJ, Yun CH, Cho CS. Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int  J Nanomedicine. 2012; 7:6077-93.

111. Isomura H, Stinski MF. Coordination of late gene transcription of human cytomegalovirus with viral DNA synthesis: recombinant viruses as potential therapeutic vaccine candidates. Expert Opin Ther Targets. 2012 Dec 12. [Epub ahead of print].

112. Jacobs B, Lindelow M, Xayyavong P, Sackett P. Building on community outreach for childhood vaccination to deliver maternal and child health services in Laos:  a feasibility assessment. Reprod Health Matters. 2012 Dec; 20(40):112-21.

113. Jain KM, Paul P, Lamontagne DS. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects. Sex Health. 2012 Dec 14. [Epub ahead of print].

114. Jayasinghe S, Macartney K. Estimating rotavirus gastroenteritis hospitalisations by using hospital episode statistics before and after the introduction of rotavirus vaccine in Australia. Vaccine. 2012 Dec 13. [Epub ahead of print].

115. Jokinen J, Palmu AA, Kilpi T. Acute otitis media replacement and recurrence in the finnish otitis media vaccine trial. Clin Infect Dis. 2012 Dec; 55(12):1673-6.

116. Kaufmann SH, Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol. 2012 Dec; 23(6):900-7.

117. Kawakatsu Y, Honda S. Individual-, family- and community-level determinants  of full vaccination coverage among children aged 12-23 months in western Kenya. Vaccine. 2012 Dec 14; 30(52):7588-93.

118. Keating GM, Plosker GL, Lyseng-Williamson KA. A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use. BioDrugs. 2012 Dec 1; 26(6):425-30.

119. Kempe A, Saville A, Dickinson LM, Eisert S, Reynolds J, Herrero D, Beaty B,  Albright K, Dibert E, Koehler V, Lockhart S, Calonge N. Population-Based Versus Practice-Based Recall for Childhood Immunizations: A Randomized Controlled Comparative Effectiveness Trial. Am J Public Health. 2012 Dec 13. [Epub ahead of  print].

120. King JC Jr, Lichenstein R, Magder LS. Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012. Vaccine. 2012 Dec 4. [Epub ahead of print].

121. King K, Paterson M, Green SK. Global justice and the proposed ban on thimerosal-containing vaccines. Pediatrics. 2013 Jan; 131(1):154-6.

122. Kositanont U, Assantachai P, Wasi C, Puthavathana P, Praditsuwan R. Kinetics of the antibody response to seasonal influenza vaccination among the elderly. Viral Immunol. 2012 Dec; 25(6):471-6.

123. Kouassi DP, Coulibaly D, Foster L, Kadjo H, N'zussuouo T, Traoré Y, Chérif D, N'gattia AK, Thompson MG. Vulnerable Groups Within a Vulnerable Population: Awareness of the A(H1N1)pdm09 Pandemic and Willingness to Be Vaccinated Among Pregnant Women in Ivory Coast. J Infect Dis. 2012 Dec; 206 Suppl 1:S114-20.

124. Košnik IG, Lah AK. A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia. Vaccine. 2012 Dec 14. [Epub ahead of print].

125. Kulkarni PS, Manjunath K, Agarkhedkar S; Group of SII IIV Studies. Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. Vaccine. 2012 Dec 17; 31(1):20-2.

126. Kusters MA, Bok VL, Bolz WE, Huijskens EG, Peeters MF, de Vries E. Influenza A/H1N1 Vaccination Response Is Inadequate in Down Syndrome Children When the Latest Cut-off Values Are Used. Pediatr Infect Dis J. 2012 Dec; 31(12):1284-5.

127. Källén B, Olausson P. Vaccination against H1N1 influenza with Pandemrix(®) during pregnancy and delivery outcome: a Swedish register study. BJOG. 2012 Dec; 119(13):1583-90.

128. Landelle C, Vanhems P, Saadatian-Elahi M, Voirin N. Influenza vaccination coverage among patients and healthcare workers in a university hospital during the 2006-2007 influenza season. Vaccine. 2012 Dec 17; 31(1):23-6.

129. Le Corre N, Thibault F, Pouteil Noble C, Meiffrédy V, Daoud S, Cahen R, Charreau I, Bottigioli D, Dollinger C, Aboulker JP, Autran B, Morelon E, Barrou B. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine. 2012 Dec 14; 30(52):7522-8.

130. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012 Dec 14; 30(52):7443-6.

131. Lee SH. Detection of human papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminum adjuvant in the HPV vaccine Gardasil®. J Inorg Biochem. 2012 Dec; 117:85-92.

132. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol.  2012 Dec 31; 162(2-3):171-82.

133. Liesenborghs L, Verhaegen J, Peetermans WE, Vandeven J, Flamaing J. Trends in serotype prevalence in invasive pneumococcal disease before and after infant pneumococcal vaccination in Belgium, 2002-2010. Vaccine. 2012 Dec 19. [Epub ahead of print].

134. Link-Gelles R, Chamberlain AT, Schulkin J, Ault K, Whitney E, Seib K, Omer SB. Missed opportunities: a national survey of obstetricians about attitudes on maternal and infant immunization. Matern Child Health J. 2012 Dec; 16(9):1743-7.

135. Luna EJ, Frazatti-Gallina NM, Timenetsky MC, Cardoso MR, Veras MA, Miraglia  JL, Escobar AM, Grisi SJ, Raw I, Precioso AR. A phase I clinical trial of a new 5-valent rotavirus vaccine. Vaccine. 2012 Dec 20.  [Epub ahead of print].

136. Marshall HS, McIntyre P, Richmond P, Buttery JP, Royle JA, Gold MS, Wood N,  Elliott EJ, Zurynski Y, Toi CS, Dwyer DE, Booy R. Changes in Patterns of Hospitalized Children with Varicella and of Associated Varicella Genotypes Following Introduction of Varicella Vaccine in Australia. Pediatr Infect Dis J. 2012 Dec 17. [Epub ahead of print].

137. Mazza D, Petrovic K, Chakraborty S. HPV vaccination of adult women: An audit of Australian general practitioners. Aust N Z J Obstet Gynaecol. 2012 Dec; 52(6):528-33.

138. McGrath LJ, Kshirsagar AV. Influenza and pneumococcal vaccination in dialysis patients: merely a shot in the arm? Am J Kidney Dis. 2012 Dec; 60(6):890-2.

139. Metcalf CJ, Lessler J, Klepac P, Cutts F, Grenfell BT. Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination. Epidemiol Infect. 2012 Dec; 140(12):2290-301.

140. Mihigo R, Torrealba CV, Coninx K, Nshimirimana D, Kieny MP, Carrasco P, Hedman L, Widdowson MA. 2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa--Successes and Challenges. J Infect Dis. 2012 Dec; 206 Suppl 1:S22-8.

141. Mishra DK, Dhote V, Mishra PK. Transdermal immunization: biological framework and translational perspectives. Expert Opin Drug Deliv. 2012 Dec 21.[Epub ahead of print].

142. Modak RM, Parris SM, Dilisi JP, Premkumar A. Increasing Influenza Vaccination Rates among Hospital Employees without a Mandatory Policy. Infect Control Hosp Epidemiol. 2012 Dec; 33(12):1288-9.

143. Moghadam MD. A new discussion for "Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: A nationwide population-based study". Prev Med. 2012 Dec 19. [Epub ahead of print].

144. Mollers M, Scherpenisse M, van der Klis FR, King AJ, van Rossum TG, van Logchem EM, Feltkamp MC, Meijer CJ, Snijders PJ, Boot HJ, de Melker HE. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol. 2012 Dec;36(6):519-24.

145. Moltenis M, Valnet-Rabier MB, Leroy J, Kantelip JP. [Safety Update on Vaccination during Pregnancy]. Therapie. 2012 Sep-Oct; 67(5):457-63.

146. Moon SJ, Lee SH, Byun YH, Yun GY, Kim SK, Seong BL, Kim AR, Sun Park E, Kim  HJ, Lee JE, Ha SK, Lee JM, Park HC. Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol. 2012 Dec 3;13(1):165. [Epub ahead of print] PubMed PMID:

147. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012 Dec; 71(12):2006-10.

148. Moscicki AB, Wheeler CM, Romanowski B, Hedrick J, Gall S, Ferris D, Poncelet S, Zahaf T, Moris P, Geeraerts B, Descamps D, Schuind A. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women. Vaccine. 2012 Dec 17; 31(1):234-41.

149. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KM, Schaffner W, Thomas A, Lexau C, Bennett NM, Farley MM, Harrison LH, Reingold A, Hadler J, Beall B, Klugman KP, Moore MR. Epidemiology of Invasive Pneumococcal Disease Among High-Risk Adults Since the Introduction of Pneumococcal Conjugate Vaccine for Children. Clin Infect Dis. 2012 Dec 18. [Epub ahead of print].           

150. Naevdal E. Fighting transient epidemics-optimal vaccination schedules before and after an outbreak. Health Econ. 2012 Dec; 21(12):1456-76.

151. Nagaoka K, Fujiwara T, Ito J. Do income inequality and social capital associate with measles-containing vaccine coverage rate? Vaccine. 2012 Dec 14; 30(52):7481-8.

152. Nagel G, Weinmayr G, Flohr C, Kleiner A, Strachan DP; ISAAC Phase Two Study  Group. Association of pertussis and measles infections and immunizations with asthma and allergic sensitization in ISAAC Phase Two. Pediatr Allergy Immunol. 2012 Dec; 23(8):737-46.

153. Nakayama T, Kumagai T, Ishii KJ, Ihara T. Alum-adjuvanted H5N1 whole virion  inactivated vaccine (WIV) induced IgG1 and IgG4 antibody responses in young children. Vaccine. 2012 Dec 14;30(52):7662-6.

154. Narwaney KJ, Glanz JM, Norris JM, Fingerlin TE, Hokanson JE, Rewers M, Hambidge SJ. Association of HLA class II genes with clinical hyporesponsiveness to trivalent inactivated influenza vaccine in children. Vaccine. 2012 Dec 19.[Epub ahead of print].

155. Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012 Dec; 45(12):1102-11.

156. Novak D, Lundgren A, Westphal S, Valdimarsson S, Olsson ML, Trollfors B. Two cases of hemolytic uremic syndrome caused by Streptococcus pneumoniae serotype 3, one being a vaccine failure. Scand J Infect Dis. 2012 Dec 28. [Epub ahead of print].

157. Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, Lawler J, McLean HQ, Pollock L, Rausch-Phung E, Schulte C, Valure B, Armstrong GL, Gallagher K. Impact of a third dose of measles mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012 Dec; 130(6):e1567-74.

158. Oldach BR, Katz ML. Ohio Appalachia public health department personnel: human papillomavirus (HPV) vaccine availability, and acceptance and concerns among parents of male and female adolescents. J Community Health. 2012 Dec; 37(6):1157-63.

159. Orenstein WA, Paulson JA, Brady MT, Cooper LZ, Seib K. Global vaccination recommendations and thimerosal. Pediatrics. 2013 Jan; 131(1):149-51.

160. Ostergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis. 2012 Dec 12. [Epub ahead of print].

161. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R, Tolo Y, Dutta S, Heppner DG, Soisson L, Diggs CL, Vekemans J, Cohen J, Blackwelder WC, Dube T, Laurens MB, Doumbo OK, Plowe CV. Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. J Infect Dis. 2012 Dec 18. [Epub ahead of print].

162. Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and  economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine. 2012 Dec 17; 31(1):96-108.

163. Palmer KT, Cosgrove M. Pneumococcal vaccination in welders. Occup Med (Lond). 2012 Dec; 62(8):666-7.

164. Palmer KT, Cosgrove M. Vaccinating welders against pneumonia. Occup Environ  Med. 2012 Dec; 69(12):932.

165. Pathirana RD, Bredholt G, Akselsen PE, Pedersen GK, Cox RJ. A(H1N1)pdm09 vaccination of health care workers: improved immune responses in low responders following revaccination. J Infect Dis. 2012 Dec 1; 206(11):1660-9.

166. Pelton SI. Increasing focus on local epidemiology demonstrates potential value of pneumococcal conjugate vaccines in Middle East and North Africa Region. Vaccine. 2012 Dec 31; 30 Suppl 6:G1.

167. Pereira JA, Quach S, Heidebrecht CL, Quan SD, Kolbe F, Finkelstein M, Kwong  JC. Barriers to the use of reminder/recall interventions for immunizations: a systematic review. BMC Med Inform Decis Mak. 2012 Dec 17; 12(1):145. [Epub ahead of print].

168. Perez-Romero P, Aydillo TA, Perez-Ordoñez A, Muñoz P, Moreno A, López-Medrano F, Bodro M, Montejo M, Gavaldà J, Carmen Fariñas M, Pachon J, Cordero E. Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect. 2012 Dec; 18(12):E533-E540.

169. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de-Miguel  MJ, Hernández-Sampelayo T, Otheo E, Méndez C. Impact of Introduction of Conjugate Vaccines in the Vaccination Schedule on the Incidence of Pediatric Invasive Pneumococcal Disease Requiring Hospitalization in Madrid (2007-2011). Pediatr Infect Dis J. 2012 Dec 17. [Epub ahead of print].

170. Pichon B, Ladhani SN, Slack MP, Segonds-Pichon A, Andrews NJ, Waight PA, Miller E, George R. Changes in the molecular epidemiology of Streptococcus pneumoniae causing meningitis following the introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol. 2012 Dec 26.  [Epub ahead of print].

171. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine. 2012 Dec 14. [Epub ahead of print].

172. Pitt JM, Blankley S, McShane H, O'Garra A. Vaccination against tuberculosis: How can we better BCG? Microb Pathog. 2012 Dec 17. [Epub ahead of print].

173. Plosker GL. Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (RotarixTM) in Developed Countries†. Drugs R D. 2012 Dec 1; 12(4):239-44.

174. Plosker GL. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (RotarixTM) in the prevention of rotavirus gastroenteritis in developing countries. Paediatr Drugs. 2012 Dec 1; 14(6):429-33.

175. Poli F, Overeem S, Lammers GJ, Plazzi G, Lecendreux M, Bassetti CL, Dauvilliers Y, Keene D, Khatami R, Li Y, Mayer G, Nohynek H, Pahud B, Paiva T, Partinen M, Scammell TE, Shimabukuro T, Sturkenboom M, van Dinther K, Wiznitzer M, Bonhoeffer J. Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. Vaccine. 2012 Dec 16. [Epub ahead of print].

176. Pons-Salort M, Letort V, Favre M, Heard I, Dervaux B, Opatowski L, Guillemot D. Exploring individual HPV coinfections is essential to predict HPV-vaccination  impact on genotype distribution: A model-based approach. Vaccine. 2012 Dec 12. [Epub ahead of print].

177. Poole T, Goodyear-Smith F, Petousis-Harris H, Desmond N, Exeter D, Pointon L, Jayasinha R. Human papillomavirus vaccination in Auckland: Reducing ethnic and socioeconomic inequities. Vaccine. 2012 Dec 17; 31(1):84-8.

178. Prinsen H, de Vries IJ, Torensma R, Pots JM, Mulder SF, van Herpen CM, Elving LD, Bleijenberg G, Stelma FF, van Laarhoven HW. Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. BMC Immunol. 2012 Dec 17; 13:71.

179. Pronker ES, Claassen E, Osterhaus AD. Development of new generation influenza vaccines: Recipes for success? Vaccine. 2012 Dec 7; 30(51):7344-7.

180. Prutsky GJ, Domecq JP, Elraiyah T, Wang Z, Grohskopf LA, Prokop LJ, Montori  VM, Murad MH. Influenza vaccines licensed in the United States in healthy children: a systematic review and network meta-analysis (Protocol). Syst Rev. 2012 Dec 29; 1(1):65. [Epub ahead of print].

181. Purohit S, Alvarez O, O'Brien R, Andreansky S. Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1280-3.

182. Rafiq S, Russell ML, Webby R, Fonseca K, Smieja M, Singh P, Loeb M. Serological Response to Influenza Vaccination among Children Vaccinated for Multiple Influenza Seasons. PLoS One. 2012; 7(12):e51498.

183. Ramakrishnan A, Althoff KN, Lopez JA, Coles CL, Bream JH. Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines. Cytokine. 2012 Dec; 60(3):661-6.

184. Richie TL, Villasante EF. Use of Adenovirus Serotype 5 Vaccine Vectors in Seropositive, Uncircumcised Men: Safety Lessons from the Step Trial. J Infect Dis. 2012 Dec 28. [Epub ahead of print].

185. Riley LE, Beigi RH. Maternal Pertussis Vaccination: Protecting Neonates From Infection. Clin Infect Dis. 2012 Dec 12. [Epub ahead of print].

186. Riphagen-Dalhuisen J, Kuiphuis JC, Procé AR, Luytjes W, Postma MJ, Hak E. Contributing factors to influenza vaccine uptake in general hospitals: an explorative management questionnaire study from the Netherlands. BMC Public Health. 2012 Dec 21; 12(1):1101. [Epub ahead of print].

187. Rodas JR, Lau CH, Zhang ZZ, Griffiths SM, Luk WC, Kim JH. Exploring predictors influencing intended and actual acceptability of the A/H1N1 pandemic vaccine: A cohort study of university students in Hong Kong. Public Health. 2012  Dec; 126(12):1007-12.

188. Rodrigues F, Iturriza-Gómara M, Marlow R, Gray J, Nawaz S, Januário L, Finn  A. The evolving epidemiology of rotavirus gastroenteritis in central Portugal with modest vaccine coverage. J Clin Virol. 2012 Dec 10.  [Epub ahead of print].

189. Romano M, Pandolfi E, Marino MG, Gesualdo F, Rizzo C, Carloni E, Macchiaiolo M, Tozzi AE. Seasonal and pandemic influenza vaccine: recommendations to families of at-risk children during the 2009-10 season. Eur J Public Health. 2012 Dec; 22(6):821-4.

190. Rouveix E, Gherissi Cherni D, Dupont C, Beauchet A, Sordet Guepet H, Gavazzi G, Gaillat J; l'intergroupe Société de pathologie infectieuse de langue française/Société de gériatrie et gérontologie clinique (SPILF/SGGC). Streptococcus pneumoniae vaccinal coverage in hospitalized elderly patients in France. Med Mal Infect. 2012 Dec 12. [Epub ahead of print].

191. Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C,  Fireman B, Sejvar JJ, Halsey NA, Baxter R; the Risk Interval Working Group of the Clinical Immunization Safety Assessment Network. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012 Dec  17; 31(1):271-277.

192. Rozenbaum MH, Postma MJ. Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands". Vaccine. 2012 Dec 11. [Epub ahead of print].

193. Rozenbaum MH, De Cao E, Westra TA, Postma MJ. Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around....Expert Rev Vaccines. 2012 Dec; 11(12):1415-28.

194. Ruck RC, Eberly MD. Development of pneumococcal mastoiditis due to multidrug-resistant serotype 19A despite three doses of 13-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol. 2012 Dec; 76(12):1849-51.

195. Salles MJ, Sens YA, Malafronte P, Souza JF, Vilas Boas LS, Machado CM. Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients. Transpl Infect Dis. 2012 Dec; 14(6):564-74.

196. Samkange-Zeeb F, Spallek L, Klug SJ, Zeeb H. HPV infection awareness and self-reported HPV vaccination coverage in female adolescent students in two German cities. J Community Health. 2012 Dec; 37(6):1151-6.

197. Schauer SL, Hopfensperger DJ, Verdon MJ, Maerz TR, Gabor GW, Davis JP. An Immunization Information System to Meet Evolving Needs During the 2009-2010 Influenza A (H1N1) Vaccination Campaign. Disaster Med Public Health Prep. 2012 Dec;6(4):402-7.

198. Schiffer JM, Maniatis P, Garza I, Steward-Clark E, Korman LT, Pittman PR, Mei JV, Quinn CP. Quantitative assessment of anthrax vaccine immunogenicity using the dried blood spot matrix. Biologicals. 2012 Dec 19. [Epub ahead of print].

199. Schindler M, Blanchard-Rohner G, Meier S, Martinez de Tejada B, Siegrist CA, Burton-Jeangros C. Vaccination against seasonal flu in Switzerland: The indecision of pregnant women encouraged by healthcare professionals. Rev Epidemiol Sante Publique. 2012 Dec; 60(6):447-53.

200. Schlaudecker EP, McNeal MM, Dodd CN, Ranz JB, Steinhoff MC. Pregnancy modifies the antibody response to trivalent influenza immunization. J Infect Dis. 2012 Dec 1; 206(11):1670-3.

201. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention  of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2012 Dec 3. [Epub ahead of print].

202. Seib K, Barnett DJ, Weiss PS, Omer SB. Vaccine-related standard of care and  willingness to respond to public health emergencies: A cross-sectional survey of  California vaccine providers. Vaccine. 2012 Dec 17; 31(1):196-201.

203. Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D, Kamtchoua T, Lashley P, Yuan T, Gurunathan S. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012 Dec 14;30(52):7455-60.

204. Sen D, Chen Y. Vaccinating welders against pneumonia. Occup Med (Lond). 2012 Dec; 62(8):665-6.

205. Shibl AM, Memish ZA, Al-Kattan KM. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA). Vaccine. 2012 Dec 31; 30 Suppl 6:G32-6.

206. Shinjo SK, de Moraes JC, Levy-Neto M, Aikawa NE, de Medeiros Ribeiro AC, Schahin Saad CG, Precioso A, Silva CA, Bonfá E. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: Immunogenicity independent of therapy and no harmful effect in disease. Vaccine. 2012 Dec 17; 31(1):202-6.

207. Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y. Cross-reactive and Vaccine-Induced Antibody to an Emerging Swine-Origin Variant of Influenza A Virus Subtype H3N2 (H3N2v). J Infect Dis. 2012 Dec; 206(12):1852-61.

208. Souayah N, Yacoub HA, Khan HM, Farhad K, Mehyar LS, Maybodi L, Menkes DL, Qureshi AI. Guillain-Barré Syndrome After Influenza Vaccination in the United States, A Report From the CDC/FDA Vaccine Adverse Event Reporting System (1990-2009). J Clin Neuromuscul Dis. 2012 Dec; 14(2):66-71.

209. Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapelière P, Moris P, Demoitié MA, Mettens P, Vinals C, Vastiau I, Jongert E, Cohen J, Ballou  WR. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: A randomized controlled phase I/II study. Tuberculosis (Edinb). 2012 Dec 4.[Epub ahead of print].

210. Stewart AM, Cox MA. State law and influenza vaccination of health care personnel. Vaccine. 2012 Dec 6. [Epub ahead of print].

211. Swamy GK, Garcia-Putnam R. Vaccine-Preventable Diseases in Pregnancy. Am J Perinatol. 2012 Dec 27. [Epub ahead of print].

212. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson  D, McNamee K, Garefalakis M, Garland SM. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012 Dec 1;206(11):1645-51.

213. Tacken MA, Jansen B, Mulder J, Visscher S, Heijnen ML, Campbell SM, Braspenning JC. Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: A cohort study from 2009 to 2011. Vaccine. 2012 Dec 16. [Epub ahead of print].

214. Tao C, He Y, Yang H, Gregory PA, Chute CG. Ontology-based time information representation of vaccine adverse events in VAERS for temporal analysis. J Biomed Semantics. 2012 Dec 20; 3(1):13. [Epub ahead of print].

215. Tetsutani K, Ishii KJ. Adjuvants in influenza vaccines. Vaccine. 2012 Dec 14; 30(52):7658-61.

216. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL. A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults. Am J Trop Med Hyg. 2012 Dec 3. [Epub ahead of print].

217. Thomas TL, Strickland OL, Diclemente R, Higgins M, Haber M. Rural African American Parents' Knowledge and Decisions About Human Papillomavirus Vaccination. J Nurs Scholarsh. 2012 Dec; 44(4):358-367.

218. Trubiano JA, Holmes NE, Williams DS, Ng J, Chua K, Howden BP. Coxiella burnetii endocarditis after Q fever vaccination. J Med Microbiol. 2012 Dec; 61(Pt 12):1775-9.

219. Trück J, Lazarus R, Jonsdottir I, Klugman KP, Pollard AJ. Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present. Clin Infect Dis. 2012 Dec; 55(11):1577-9; author reply 1579-81.

220. Uchida S, Sakai A, Nakamura T. Subacromial bursitis following human papilloma virus vaccine misinjection. Vaccine. 2012 Dec 17; 31(1):27-30.

221. Uno S, Kimachi K, Matsuo F, Miyazaki K, Oohama A, Kei J, Nishimura T, Odoh K, Kino Y. Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan. Microbiol Immunol. 2012 Dec; 56(12):810-6.

222. Valour F, Bénet T, Chidiac C; for the study group. Pandemic A(H1N1)2009 influenza vaccination in Lyon University Hospitals, France: Perception and attitudes of hospital workers. Vaccine. 2012 Dec 7. [Epub ahead of print].

223. Van Holle L, Bauchau V. Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization. Pharmacoepidemiol Drug Saf. 2012 Dec 17. [Epub ahead of print].

224. Velentgas P, Amato AA, Bohn RL, Arnold Chan K, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012 Dec; 21(12):1350-8.

225. Verma R, Khanna P. Meningococcal vaccine: A new vaccine to combat meningococcal disease in India. Hum Vaccin Immunother. 2012 Dec 1; 8(12). [Epub ahead of print].

226. Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, Fortuno ES, Xu W, Shi L, Kukreti V, Crump M, Kuruvilla J. Evaluation of 2009 Pandemic H1N1 Influenza Vaccination in Adults with Lymphoid Malignancies receiving Chemotherapy or Following Autologous Stem Cell Transplantation. Leuk Lymphoma. 2012 Dec 14. [Epub ahead of print].

227. Voelker R. Study finds Tdap vaccine is safe for older adults. JAMA. 2012 Dec 26; 308(24):2555.

228. Wakadha H, Chandir S, Were EV, Rubin A, Obor D, Levine OS, Gibson DG, Odhiambo F, Laserson KF, Feikin DR. The feasibility of using mobile-phone based SMS reminders and conditional cash transfers to improve timely immunization in rural Kenya. Vaccine. 2012 Dec 12.  [Epub ahead of print].

229. Wang IJ, Huang LM, Guo YL, Hsieh WS, Lin TJ, Chen PC. Haemophilus influenzae type b combination vaccines and atopic disorders: A prospective cohort study. J Formos Med Assoc. 2012 Dec; 111(12):711-8.

230. Wang S, Diao N, Lu C, Wu J, Gao Y, Chen J, Zhou Z, Huang H, Shao L, Jin J, Weng X, Zhang Y, Zhang W. Evaluation of the Diagnostic Potential of IP-10 and IL-2 as Biomarkers for the Diagnosis of Active and Latent Tuberculosis in a BCG-Vaccinated Population. PLoS One. 2012;7(12):e51338.

231. Wardrope A. Scarce vaccine supplies in an influenza pandemic should not be distributed randomly: reply to McLachlan. J Med Ethics. 2012 Dec;38(12):765-7.

232. Waters EK. Aggregation and competitive exclusion: explaining the coexistence of human papillomavirus types and the effectiveness of limited vaccine conferred  cross-immunity. Acta Biotheor. 2012 Dec; 60(4):333-56.

233. Weckx LY, Thompson A, Berezin EN, Faria SM, Cunha CA, Pride M, Patterson S,  Gruber WC, Emini EA, Scott DA; On behalf of the 012 Study Group. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012 Dec 14; 30(52):7566-7572.

234. Wieten RW, Leenstra T, van Thiel PP, van Vugt M, Stijnis C, Goorhuis A, Grobusch MP. Rabies Vaccinations: Are Abbreviated Intradermal Schedules the Future? Clin Infect Dis. 2012 Dec 12. [Epub ahead of print].

235. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, Svanström H,  Mølgaard-Nielsen D, Heijbel H, Dahlström LA, Hallgren J, Sparen P, Jennum P, Mosseveld M, Schuemie M, van der Maas N, Partinen M, Romio S, Trotta F, Santuccio C, Menna A, Plazzi G, Moghadam KK, Ferro S, Lammers GJ, Overeem S, Johansen K, Kramarz P, Bonhoeffer J, Sturkenboom MC. The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2012 Dec 13. [Epub ahead of print].

236. Wilson SE, Harris T, Sethi P, Fediurek J, Macdonald L, Deeks SL. Coverage from Ontario, Canada's school-based HPV vaccine program: The first three years. Vaccine. 2012 Dec 13. [Epub ahead of print].

237. Woldeamanuel YW. Tetanus in Ethiopia: unveiling the blight of an entirely vaccine-preventable disease. Curr Neurol Neurosci Rep. 2012 Dec; 12(6):655-65.

238. Wójcik OP, Simonsen J, Mølbak K, Valentiner-Branth P. Validation of the 5-year tetanus, diphtheria, pertussis and polio booster vaccination in the Danish childhood vaccination database. Vaccine. 2012 Dec 13. [Epub ahead of print].

239. Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies. Pharmacoepidemiol Drug Saf. 2012 Dec; 21(12):1359-60.

240. Zheng D, Yi Y, Chen Z. Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza. Viruses. 2012 Dec 10; 4(12):3589-605.

 [Top]